Stephen Tyring
Expertise in
39
conditions

Dr. Stephen Tyring

Dermatology
20320 Northwest Fwy # 700, 
Jersey Village, TX 
Expertise in
39
conditions
20320 Northwest Fwy # 700, 
Jersey Village, TX 

Overview

Stephen Tyring is a Dermatologist practicing medicine in Jersey Village, Texas.

Dr. Tyring is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Shingles, Plaque Psoriasis, Psoriasis, and Warts.

He is actively involved in clinical research, co-authoring 364 peer reviewed articles and participating in 14 clinical trials.

Specialties

Dermatology

Licenses

Dermatology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 25 Less Insurance Carriers -

Locations

20320 Northwest Fwy # 700, Jersey Village, TX 77065
Other Locations
1401 Binz St # 200, Houston, TX 77004
451 N Texas Ave, Webster, TX 77598

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 26, 2024
Intervention Type: Drug, Biological
Study Drug: ASLAN004
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Biological
Study Drug: CDX-0159
Study Phase: Phase 1
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 4
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
View 9 Less Clinical Trials

364 Total Publications

Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics.
Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics.
Journal: Journal of cutaneous medicine and surgery
Published: March 30, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Michael Migden
Dermatology
Expertise in
9
conditions
Dr. Michael Migden
Dermatology

Office

1400 Pressler St Unit 1452, 
Houston, TX 
 (1.5 miles away)
713-563-1665
Languages Spoken:
English
See accepted insurances

Michael Migden is a Dermatologist practicing medicine in Houston, Texas. Dr. Migden is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Melanoma, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Expertise in
39
conditions
Dr. Leonard Goldberg
Dermatology
Expertise in
39
conditions
Dr. Leonard Goldberg
Dermatology

DermSurgery Associates

6700 West Loop S Ste 500, 
Bellaire, TX 
 (4.7 miles away)
281-817-4975
Languages Spoken:
English
See accepted insurances

Leonard Goldberg is a Dermatologist practicing medicine in Bellaire, Texas. Dr. Goldberg is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Actinic Keratosis, and Universal Acquired Melanosis.

Expertise in
64
conditions
Dr. Greg Pearson
Dermatology
Expertise in
64
conditions
Dr. Greg Pearson
Dermatology

Greg Willaim Pearson MD

915 Gessner Rd Ste 860, 
Houston, TX 
 (8.4 miles away)
713-468-2200
Languages Spoken:
English
See accepted insurances

Greg Pearson is a Dermatologist practicing medicine in Houston, Texas. Dr. Pearson is highly rated in 64 conditions, according to our data. His clinical expertise encompasses Seborrheic Keratosis, Contact Dermatitis, Warts, and Actinic Keratosis.

Frequently Asked Questions about Dr. Stephen Tyring

How do I make an appointment with Dr. Stephen Tyring?

You can book an appointment with Dr. Stephen Tyring by calling their office at 409-772-2222. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen Tyring a top-rated expert for Shingles?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen Tyring is classified as an Elite expert for Shingles, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen Tyring specialize in?

While Dr. Stephen Tyring is a Dermatology, they have specific expertise in Shingles, Plaque Psoriasis, and Psoriasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Stephen Tyring participate in research or clinical trials?

Yes. Dr. Stephen Tyring has published 364 articles and abstracts on conditions like Shingles. You can view a list of Dr. Stephen Tyring's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephen Tyring accept my insurance?

Dr. Stephen Tyring accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 409-772-2222 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tyring's expertise for a condition
ConditionClose
View All 28 Advanced Conditions
View All 88 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile